SCHEMBL4028398

SCHEMBL4028398

COc1ccc(S(=O)(=O)N(C)CCO)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.49
GSTO1 P78417 3/20 0.48
BDKRB1 P46663 1/20 0.47
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
TRPV4 Q9HBA0 2/20 0.41
MMP1 P03956 1/20 0.40
MMP7 P09237 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
HTR6 P50406 1/20 0.39
KMT2A Q03164 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6184726 0.87 ACLY (0.47) ACLYGSTO1BDKRB1ALDH1A1LMNA
SCHEMBL11947869 0.82 ALDH1A1 (0.59) ACLYBDKRB1ALDH1A1LMNATSHR
SCHEMBL5117768 0.81 BDKRB1 (0.57) ACLYGSTO1BDKRB1ALDH1A1LMNA
SCHEMBL3993365 0.81 GSTO1 (0.42) ACLYGSTO1BDKRB1ALDH1A1KDM4E
SCHEMBL20489033 0.81 TSHR (0.51) ACLYGSTO1ALDH1A1KDM4EHTT
SCHEMBL4031734 0.76 GSTO1 (0.54) GSTO1ALDH1A1KDM4EHTTKMT2A
SCHEMBL11739875 0.76 ALDH1A1 (0.42) ACLYGSTO1BDKRB1ALDH1A1KDM4E
SCHEMBL29811921 0.74 PGR (0.52) ALDH1A1KDM4EKMT2ARXFP1MEN1
SCHEMBL18700925 0.74 PRKAB2 (0.48) ACLYALDH1A1TRPV4
SCHEMBL3999966 0.72 GSTO1 (0.51) GSTO1BDKRB1ALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 ACLY 2523/4885GSTO1 392/4885BDKRB1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.